Imane Chaoui

Imane Chaoui

Auto-generated profile, based on publicly available information

Imane Chaoui

Department of Life Sciences, National Centre for Nuclear Energy, Science and Technology, Rabat, Morocco

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Annals of Cancer Research and Therapy
Verified
Journal Article
Open access
PDF file
CAChaimae Hafidi Alaoui
Chaimae Hafidi Alaoui
HAHajar El Ahanidi
Hajar El Ahanidi
MAMeryem EL AZZOUZI
Meryem EL AZZOUZI
AFAbdelkarim Filali-Maltouf
Abdelkarim Filali-Maltouf
ICImane Chaoui
Imane Chaoui
MMMohammed EL MZIBRI
Mohammed EL MZIBRI
Background: Human telomerase reverse transcriptase (hTERT) promoter mutations are common genetic events in bladder cancer (BC) and have been recognized as potential biomarkers for BC diagnosis and prognosis. Detection of TERT promoter mutations as urine-based tests has previously been reported to detect primary and recurrent BC. This study was planned to evaluate hTERT promoter mutations in both biopsies and urines from BC patients to assess the interest and the usefulness of introducing these biomarkers for better management of BC in Morocco. Methods: In a cohort study involving a series of BC 70 patients with different stages and grades, hTERT promoter mutations were identified in both fresh biopsies and urine sediments by PCR amplification and DNA sequencing. Results: Overall, hTERT promoter mutations were reported in 60% of cancer biopsies (42/70), the hotspot mutations C228T and C250T were respectively identified in 80.95% (34/42) and 16.67% (7/42) of positive cases. Other mutations: A161C and G149T were also reported and were obtained in 2.38% (1/42) and 2.38% (1/42), respectively. hTERT promoter mutations were identified in 30% of matched urine sediments (21/70) and showed an overall sensitivity of 50% and specificity of 100%. In patients with non-muscle invasive bladder cancer, no statistically significant association was detected between TERT promoter mutations and recurrence-free survival (HR: 1.224, 95% CI: 0.373–4.011, p = 0.739), and overall survival (HR: 0.363, 95% CI: 0.041–3.244, p = 0.364). Conclusion: hTERT promoter mutations are early events occurring with high frequencies and can be identified in the exfoliated cells, making them an interesting non-invasive biomarker for diagnosis and follow-up of bladder cancer.

1 April 2023 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Closed access
PDF file
RBRajaa Benzeid
Rajaa Benzeid
AGAmina Gihbid
Amina Gihbid
NBNadia Benchekroun
Nadia Benchekroun
NTNezha Tawfiq
Nezha Tawfiq
ABAbdellatif Benider
Abdellatif Benider
ICImane Chaoui
Imane Chaoui
Nasopharyngeal cancer (NPC) is one of the most common head and neck cancers. NPC differs significantly from other cancers in its etiology, epidemiology, clinical behavior, and treatment. Being highly radiosensitive, the standard treatment for NPC is radiotherapy. However, radioresistance hampers the success of treatment and may cause local recurrence and distant metastases in NPC patients. In this review, we discuss the updated protocols for NPC diagnosis and treatment based on recent literature with an emphasis on the mechanisms of radioresistance at the molecular level with a special focus on genetic and epigenetic events, affecting genes involved in xenobiotic detoxification and DNA repair. We also highlight the importance of some cellular and Epstein Barr viral miRNAs targeting specific DNA repair factors and consequently promoting NPC radioresistance. These molecular markers may serve as promising tools for diagnosis, prognosis, and radioresistance prediction to guide theranostics of patients with NPC in the future.